| Literature DB >> 33182763 |
Jelena Vladić1, Tatjana Ćebović2, Senka Vidović1, Stela Jokić3.
Abstract
Satureja montana herbal species belongs to aromatic medicinal plants with a significant place in traditional medicine. However, products produced with conventional procedures do not meet the requirements of the modern market which include environmentally-safe processes that provide quality, safe, and standardized products. In this study, the antiproliferative activity of S. montana extracts obtained by supercritical carbon dioxide and solid-liquid extraction followed by spray drying was investigated using the in vivo model of Ehrlich ascites carcinoma (EAC) in mice. The impact of two concentrations of extracts on the growth of tumor and the redox status of malignant cells was monitored. It was determined that the extracts induced oxidative stress in the malignant cells which was confirmed by the changes in activity of biochemical indicators of oxidative stress. The posttreatment was not an efficient approach, while the extracts applied as pretreatment and treatment resulted in an increase in the xanthine oxidase (XOD) activity, a decrease in catalase (CAT) activity, and an increase in the intensity of lipid peroxidation (LPx). Furthermore, a decrease in the values of reduced glutathione (GSH) and an increase in glutathione reductase (GR) and glutathione peroxidase (GSHPx) in EAC cells were recorded.Entities:
Keywords: Ehrlich ascites tumor; Satureja montana; carvacrol; cytotoxic activity; spray drying; supercritical carbon dioxide; winter savory
Year: 2020 PMID: 33182763 PMCID: PMC7696860 DOI: 10.3390/plants9111532
Source DB: PubMed Journal: Plants (Basel) ISSN: 2223-7747
Figure 1Impact of S. montana extracts on (a) Ehrlich ascites carcinoma (EAC) ascites volume, (b) EAC cells viability, and (c) EAC cells number (SD—spray-dried extract; SC—extract obtained by Sc-CO2).
Impact of S. montana extracts on the volume of ascites.
| Group | EAC Ascites Volume (mL) | |||
|---|---|---|---|---|
| EAC Control | 7.117 ± 0.458 | |||
| Extract | SD1 | SD5 | SC1 | SC5 |
| Pretreatment | 2.267 ± 1.178 a,* | 3.283 ± 1.301 a,* | 2.267 ± 0.674 a,* | 1.000 ± 0.469 a,* |
| Treatment | 2.167 ± 0.288 ab,* | 0.817 ± 0.147 b,* | 2.933 ± 1.147 a,* | 2.267 ± 1.065 ab,* |
| Post-treatment | 3.083 ± 0.382 b,* | 9.657 ± 0.359 a,* | 9.851 ± 0.932 a,* | 9.622 ± 0.954 a,* |
Results are presented as a mean value ± SD from six mice. *—statistically significant difference compared to the EAC control group; different letters within a row indicate a significant difference between the samples in the same group at p < 0.05.
Impact of S. montana extracts on the viability of EAC cells.
| Group | EAC Cells Viability (%) | |||
|---|---|---|---|---|
| EAC Control | 7.243 ± 1.425 | |||
| Extract | SD1 | SD5 | SC1 | SC5 |
| Pretreatment | 7.183 ± 1.705 a | 6.267 ± 0.965 a | 5.967 ± 0.339 a | 6.250 ± 1.205 a |
| Treatment | 4.817 ± 1.042 a,* | 6.550 ± 0.509 a | 6.733 ± 0.857 a | 6.200 ± 1.131 a |
| Post-treatment | 6.533 ± 0.476 a | 7.650 ± 0.874 a | 7.499 ± 0.356 a | 7.586 ± 1.023 a |
Results are presented as a mean value ± SD from six mice. *—statistically significant difference compared to the EAC control group; different letters within a row indicate a significant difference between the samples in the same group at p < 0.05.
Impact of S. montana extracts on the number of EAC cells.
| Group | EAC Cells Number/mm3 | |||
|---|---|---|---|---|
| EAC Control | 119 583.333 ± 6 755.862 | |||
| Extract | SD1 | SD5 | SC1 | SC5 |
| Pretreatment | 196,583.333 | 158,833.333 | 147,000.000 | 125,583.333 |
| Treatment | 247,000.000 | 114,333.300 | 112,166.700 | 108,000.000 |
| Post-treatment | 141,833.333 | 346,569.58 | 374,511.22 | 361,581.47 |
Results are presented as a mean value ± SD from six mice. *—statistically significant difference compared to the EAC control group; different letters within a row indicate a significant difference between the samples in the same group at p < 0.05.
Impact of S. montana extracts on biochemical parameters in EAC cells.
| Parameter | Group | EAC | SD1 | SD5 | SC1 | SC5 |
|---|---|---|---|---|---|---|
| XOD | Pretreatment | 0.156 ± 0.009 | 0.142 ± 0.004 b | 0.151 ± 0.005 b | 0.807 ± 0.138 a,* | 0.822 ± 0.057 *,a |
| Treatment | 0.104 ± 0.011 c,* | 0.836 ± 0.069 b,* | 1.035 ± 0.064 a,* | 1.012 ± 0.014 a,* | ||
| Posttreatment | 0.220 ± 0.014 a,* | 0.102 ± 0.005 b,* | 0.097 ± 0.012 b,* | 0.101 ± 0.004 b,* | ||
| CAT | Pretreatment | 0.503 ± 0.013 | 0.585 ± 0.019 a,* | 0.429 ± 0.002 b,* | 0.233 ± 0.016 c,* | 0.136 ± 0.002 d* |
| Treatment | 0.636 ± 0.027 a,* | 0.138 ± 0.002 c,* | 0.194 ± 0.006 b,* | 0.191 ± 0.003 b,* | ||
| Post-treatment | 0.316 ± 0.008 b,* | 0.698 ± 0.052 a,* | 0.713 ± 0.002 a,* | 0.742 ± 0.041 a,* | ||
| Px | Pretreatment | 0.325 ± 0.023 | 0.302 ± 0.016 c | 0.432 ± 0.010 c,* | 0.618 ± 0.003 b,* | 0.881 ± 0.019 a,* |
| Treatment | 0.120 ± 0.006 c,* | 0.875 ± 0.035 a,* | 0.715 ± 0.004 b,* | 0.710 ± 0.002 b,* | ||
| Post-treatment | 0.474 ± 0.035 a,* | 0.100 ± 0.008 b,* | 0.114 ± 0.023 b,* | 0.118 ± 0.007 b,* | ||
| GR | Pretreatment | 2.187 ± 0.107 | 2.115 ± 0.165 b | 3.012 ± 0.105 b,* | 4.957 ± 0.135 a,* | 5.707 ± 0.667 a,* |
| Treatment | 1.202 ± 0.095 b,* | 5.627 ± 0.363 a,* | 5.172 ± 0.111 a,* | 5.195 ± 0.024 a,* | ||
| Post-treatment | 3.930 ± 0.217 a,* | 1.195 ± 0.002 b,* | 1.254 ± 0.028 b,* | 1.284 ± 0.185 b,* | ||
| GSHPx | Pretreatment | 0.779 ± 0.048 | 0.796 ± 0.024 d | 0.933 ± 0.022 c,* | 1.302 ± 0.049 b,* | 1.697 ± 0.038 a,* |
| Treatment | 0.474 ± 0.034 b,* | 1.91 ± 0.345 a,* | 2.043 ± 0.020 a,* | 2.007 ± 0.031 a,* | ||
| Post-treatment | 1.131 ± 0.151 a,* | 0.395 ± 0.065 b,* | 0.401 ± 0.068 b,* | 0.421 ± 0.005 b,* | ||
| GSH | Pretreatment | 1.603 ± 0.110 | 1.417 ± 0.056 a,* | 1.358 ± 0.029 a,* | 0.871 ± 0.033 b,* | 0.884 ± 0.043 b,* |
| Treatment | 1.513 ± 0.058 a,* | 0.926 ± 0.069 b,* | 0.621 ± 0.011 c,* | 0.635 ± 0.005 c,* | ||
| Post-treatment | 1.105 ± 0.063 b,* | 1.801 ± 0.045 a,* | 1.799 ± 0.029 a,* | 1.842 ± 0.003 a,* | ||
| LPx | Pretreatment | 0.032 ± 0.008 | 0.030 ± 0.009 c | 0.041 ± 0.003 c | 0.100 ± 0.007 a,* | 0.080 ± 0.005 b,* |
| Treatment | 0.022 ± 0.005 c | 0.042 ± 0.521 b | 0.077 ± 0.005 a | 0.083 ± 0.005 a | ||
| Post-treatment | 0.056 ± 0.018 a,* | 0.011 ± 0.006 b,* | 0.019 ± 0.006 b,* | 0.014 ± 0.001 b,* |
Results are presented as a mean value ± SD from six mice. *—statistically significant difference compared to the EAC control group; different letters within a row indicate a significant difference between the samples in the same group at p < 0.05.
GC/MS analysis of extract obtained by Sc-CO2 ((SC) extract) and essential oil isolated from spray-dried (SD) extract (relative percentage; %) [32,33].
| Compound | SC | SD |
|---|---|---|
| α-Terpinene | 0.15 | n.i. |
| 3.96 | 0.36 | |
| γ-Terpinene | 0.80 | n.i. |
| α-Terpineol | n.i. | 0.21 |
| Eucalyptol | 0.42 | n.i. |
| 0.33 | n.i. | |
| 0.15 | n.i. | |
| Linalool | 0.29 | 0.18 |
| Borneol | 1.56 | n.i. |
| Terpinen 4-ol | 0.84 | 0.42 |
| Carvacrol | 78.61 | 71.82 |
| 2.40 | 0.24 | |
| Caryophyllene oxide | 1.26 | 1.31 |
| α-Amorphen | 0.46 | n.i. |
| β-Bisabolene | 0.74 | n.i. |
| γ-Cadinene | 0.53 | n.i. |
| δ-Cadinene | 0.78 | n.i. |
| β-Cadinene | n.i. | 0.24 |
| Spatulenol | n.i. | 0.21 |
| Heptakosane | 0.17 | n.i. |
| Nonakosane | 0.19 | n.i. |
n.i. not identified.
Biochemical parameters of control group and the groups treated with the SD1 and SC1 extracts [36].
| Group | XOD | CAT | Px | GR | GSH-Px | GSH | LPx |
|---|---|---|---|---|---|---|---|
| Control | 1.93 ± 0.02 a | 9.56 ± 0.37 b | 10.68 ± 1.38 b | 6.13 ± 0.07 a | 8.70 ± 0.38 a | 4.98 ± 0.16 a | 3.04 ± 0.07 a |
| SC | 1.87 ± 0.03 ab | 13.4 ± 0.59 a | 14.88 ± 0.38 a | 7.03 ± 0.46 a | 7.54 ± 2.23 a | 4.99 ± 0.17 a | 2.62 ± 0.54 a |
| SD | 1.86 ± 0.03 b | 12.37 ± 0.18 a | 14.57 ± 0.80 a | 6.53 ± 1.61 a | 6.67 ± 1.06 a | 4.92 ± 0.39 a | 2.21 ± 0.24 a |
Values are expressed as mean ± standard deviation for six mice. Activities of xanthine oxidase (XOD), catalase (CAT), peroxidase (Px), glutathione reductase (GR) and glutathione peroxidase (GSHPx) are expressed in nmol/mg of protein min-1. Content of hepatic reduced glutathione (GSH) is expressed in nmolGSH/mg of protein. Intensity of lipid peroxidation (LPx) is expressed in nmol/MDA/mg of protein; MDA, malonyldialdehyde. Different letters within a column indicate a significant difference between the samples at p < 0.05.